Invention Grant
- Patent Title: Therapeutic binding molecules
- Patent Title (中): 治疗结合分子
-
Application No.: US11297317Application Date: 2005-12-08
-
Publication No.: US07825222B2Publication Date: 2010-11-02
- Inventor: Gregorio Aversa , Frank Kolbinger , Josè M Carballido Herrera , András Aszódi , José W Saldanha , Bruce M Hall
- Applicant: Gregorio Aversa , Frank Kolbinger , Josè M Carballido Herrera , András Aszódi , José W Saldanha , Bruce M Hall
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Priority: GB0103389.3 20011202
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/46
Abstract:
A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
Public/Granted literature
- US20060088525A1 Therapeutic binding molecules Public/Granted day:2006-04-27
Information query
